Jeffrey S. Weber, MD, PhD, an expert in immunotherapy and melanoma, will join the senior faculty of NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. Dr. Weber will serve as Deputy Director of the Perlmutter Cancer Center and Codirector of its Melanoma Program and will oversee its work in experimental therapeutics. He officially joins the NYU Langone faculty on November 2, 2015.
Dr. Weber’s research, which has been continuously funded by the National Cancer Institute (NCI) for over 20 years, focuses on experimental therapeutics and drug development, particularly in the areas of immunotherapy and checkpoint inhibitory antibody development in melanoma and other types of cancer. Specifically, his laboratory monitors and characterizes how T cells respond in patients undergoing immunotherapy. Recently, Dr. Weber has led or been a major participant in multiple cutting-edge trials using immune effector cells called tumor-infiltrating lymphocytes and other agents to boost cancer immunity utilizing novel agents (such as CTLA-4 and PD-1) to inhibit important checkpoint molecules on T cells.
Roles in Research, Treatment, Education, and Administration
Prior to joining NYU Langone and its Perlmutter Cancer Center, Dr. Weber served since 2007 as a Senior Member of the H. Lee Moffitt Cancer Center and Director of its Donald A. Adam Comprehensive Melanoma Research Center. He also held the title of Professor in the Department of Oncologic Sciences at the University of South Florida. In addition, he has been the Principal Investigator and Director of Moffitt’s Skin Cancer SPORE (P50) NCI grant.
Before his time at Moffitt, Dr. Weber served for over 10 years at the University of Southern California (USC) Norris Comprehensive Cancer Center, rising to the positions of Chief of Medicine and Chief of the Division of Medical Oncology.
Dr. Weber has published more than 150 peer-reviewed articles. He has also served on the NCI’s Clinical Oncology Study Section, as well as the boards of the Melanoma Research Foundation and the Melanoma Therapeutics Foundation, and was Chair of the U.S. Veterans Administration’s Clinical Oncology Study Section.
Dr. Weber earned his doctorate in molecular cell biology at The Rockefeller University, and his medical degree from NYU School of Medicine. He completed internship and residency training at the University of California San Diego and fellowship training in medical oncology and tumor immunology at the NCI. ■
